Insights for your outreach

Department Breakdown

Top Biopharma Companies in Switzerland

Name: Top Biopharma Companies in Switzerland
Creator: Surfe
Published: 2025-09-30 16:09:53
License: https://creativecommons.org/licenses/by-nc/4.0/

Last updated:30 Sep 2025

Created by Surfe | Views: 9

Market context behind this list

Sort by

Companies

Key Contacts

Annual Revenue

Funding

Company Growth

Team Growth

Hiring Status

Clear all

Annual Revenue

0-1M

1-10M

10-50M

50-100M

100-500M

500-1,000M

>1,000M

Clear all

Company Growth

1-20%

20-50%

50-100%

100%+

Clear all

Team Growth

1-20%

20-50%

50-100%

100%+

Clear all

Location

Baar, Switzerland

Horgen, Switzerland

Schlieren, Switzerland

Zug, Switzerland

Raleigh, North Carolina, United States

Zurich, Switzerland

Dittingen, Switzerland

Geneva, Switzerland

Etagnières, Switzerland

Tägerwilen, Switzerland

Walchwil, Switzerland

Bern, Switzerland

Saint-Blaise, Switzerland

Balerna, Switzerland

Meyrin, Switzerland

Solothurn, Switzerland

Monthey, Switzerland

Wollerau, Switzerland

Allschwil, Switzerland

Switzerland 🇨🇭, Switzerland

Hünenberg, Switzerland

Muttenz, Switzerland

Bilthoven, Netherlands

Chamblon, Switzerland

Stein am Rhein, Switzerland

Pully, Switzerland

Schindellegi, Switzerland

Gstaad, Switzerland

Rümlang, Switzerland

Lugano, Switzerland

Mezzovico-Vira, Switzerland

Urdorf, Switzerland

Bubendorf, Switzerland

Montreux, Switzerland

Épalinges, Switzerland

Rapperswil-Jona, Switzerland

Reinach, Switzerland

Aesch, Switzerland

Basel, Switzerland

Lausanne, Switzerland

Zürich, Switzerland

Frauenfeld, Switzerland

Pfäffikon, Switzerland

Matzingen, Switzerland

Wadenswil, Switzerland

Plan-les-Ouates, Switzerland

Epalinges, Switzerland

Clear all

	Companies		Key Contacts		Annual Revenue	Funding	Company Growth	Management Team Growth	Hiring Status	Tech Stack	HQ Location
1	CDR-Life AG Biotechnology	55	Vice President of Clinical Operations, Technical Scientist- Small Scale Production, Head of Clinical Manufacturing	+63	$1-10M	$76M raised Series A, 04-13-2022	📊 Modest Growth: 3.77% 53 ↗ 55 Employees	📊 Modest Growth: 16.67% 6 ↗ 7 Employees	Not Hiring	20	Horgen, Switzerland
2	Idorsia Health Care	653	Team Leader Automated Chemistry & HTMC, Principal Scientific Associate, Associate Director, Team leader High Throughput Medicinal Chemistry	>100	$100-500M	$83M raised Post-IPO Debt, 06-20-2023	📉 Negative Growth: -3.55% 677 ↘ 653 Employees	📊 Modest Growth: 11.11% 9 ↗ 10 Employees	Actively Hiring	13	Allschwil, Switzerland
3	Roche Biotechnology	45,748	Customer Experience Specialist (Japanese Speaking), Senior Engineer Post-Market Quality, B. Sc. Pharm	>100	$>1,000M	$5,000M raised Post-IPO Equity, 08-04-2021	📊 Modest Growth: 0.9% 45,342 ↗ 45,748 Employees	📊 Modest Growth: 0.33% 303 ↗ 304 Employees	Actively Hiring	15	Switzerland 🇨🇭, Switzerland
4	Evitria Biopharma	17	Senior Director, Business Development, Office and Logistic Manager, Laborantin	+22	$1-10M		📊 Modest Growth: 6.25% 16 ↗ 17 Employees	⏸️ No Growth: 0% 3 Employees	Not Hiring	19	Schlieren, Switzerland
5	Covis Pharma Health Care	129	Senior Planner, Global product Supply, Handyman, Electrical Engineer	>100	$10-50M		⏸️ No Growth: 0% 129 Employees	⏸️ No Growth: 0% 6 Employees	Not Hiring	20	Zug, Switzerland
6	Neurimmune Holding Biotechnology	41	Senior Research Associate, Research Associate, Senior Director Translational Medicine	+52	$10-50M	$150M raised Venture Round, 10-25-2017	📊 Modest Growth: 2.5% 40 ↗ 41 Employees	⏸️ No Growth: 0% 4 Employees	Not Hiring	8	Schlieren, Switzerland
7	IBR Institute for Biopharmaceutical Research Biotechnology	8	Head of Talent Acquisition, Operations, Advisory Board Member	+7	$1-10M		⏸️ No Growth: 0% 8 Employees	⏸️ No Growth: 0% 1 Employees	Not Hiring	13	Matzingen, Switzerland
8	Adaptyv Biotechnology	16	Bioengineer, Product Engineer, Lab Automation Engineer	+13	$100-500M	$110k raised Debt Financing, 06-01-2023	📊 Modest Growth: 14.29% 14 ↗ 16 Employees	⏸️ No Growth: 0% 2 Employees	Actively Hiring	22	Épalinges, Switzerland
9	Berger AND Kraft Medical Sp z o.o. Health Care	146	Operations Director / Board Member, Inżynier produkcji, Inżynier elektronik	+18	$50-100M		⏸️ No Growth: 0% 146 Employees	⏸️ No Growth: 0% 12 Employees	Actively Hiring	21	Raleigh, North Carolina, United States
10	European Society for Medical Oncology Biotechnology	313	Communications Specialist, Chief Information and Digital Officer - Information Technology & Digital Solutions, Scientific projects coordinator	>100	$1-10M		📊 Modest Growth: 1.29% 309 ↗ 313 Employees	⏸️ No Growth: 0% 4 Employees	Actively Hiring	16	Lugano, Switzerland
11	Alpex Pharma Biotechnology	25	Deputy Warehouse Manager, Production Planner, President & Chairman	+36	$10-50M	$9M raised Series B, 08-22-2007	⏸️ No Growth: 0% 25 Employees	⏸️ No Growth: 0% Employees	Not Hiring	13	Mezzovico-Vira, Switzerland
12	Marker Biotechnology	6	General Counsel, Vice President, Operations, Principal Scientist	+7	$1-10M		⏸️ No Growth: 0% 6 Employees	⏸️ No Growth: 0% Employees	Not Hiring	7	Hünenberg, Switzerland
13	Neovii Biotechnology	51	Dialysis Tech, Quality Manager, Head of Quality Control and Analytical Development	>100	$10-50M		📉 Negative Growth: -1.92% 52 ↘ 51 Employees	⏸️ No Growth: 0% 2 Employees	Actively Hiring	19	Rapperswil-Jona, Switzerland
14	Memo Therapeutics AG Biopharma	29	Vice President, Clinical Operations, Scientist, Chief Medical Officer	+26	$1-10M	$22M raised Series C, 05-07-2024	⏸️ No Growth: 0% 29 Employees	⏸️ No Growth: 0% 8 Employees	Not Hiring	23	Schlieren, Switzerland
15	Biolytix Biotechnology	12	Biologielaborantin bei Biolytix AG, CEO, Head of Microbiology, Food and Agro	+19	$1-10M		⏸️ No Growth: 0% 12 Employees	⏸️ No Growth: 0% 3 Employees	Not Hiring	23	Dittingen, Switzerland
16	Interpharma Pharmaceutical	50	Materials Control Manager, Export Executive, Leiter Governmental Affairs und Standort, Mitglied der GL	+78	$10-50M		📉 Negative Growth: -3.85% 52 ↘ 50 Employees	⏸️ No Growth: 0% 10 Employees	Actively Hiring	34	Basel, Switzerland
17	Grl Biotechnology	13	Self Employed, obras, Asistente	+60	$10-50M		⏸️ No Growth: 0% 13 Employees	⏸️ No Growth: 0% Employees	Not Hiring	2	Geneva, Switzerland
18	Redbiotec AG Biotechnology		Data Entry Specialist, DSP Engineer	+2	$1-10M		⏸️ No Growth: 0% Employees	⏸️ No Growth: 0% Employees	Not Hiring	19	Schlieren, Switzerland
19	Inofea AG Biotechnology	10	Research and Development Group Lead, Scientist in enzymatic bioconjugation, Scientific Lab Associate	+8	$1-10M		⏸️ No Growth: 0% 10 Employees	⏸️ No Growth: 0% 4 Employees	Not Hiring	12	Muttenz, Switzerland
20	Numab Therapeutics AG Biopharma	58	Research Associate, Director, Group Leader Cell Biology & Pharmacology, Director Project Leader R&D	+61	$1-10M	$54M raised Series C, 01-09-2025	📊 Modest Growth: 3.57% 56 ↗ 58 Employees	⏸️ No Growth: 0% 7 Employees	Not Hiring	0	Wadenswil, Switzerland
21	Basilea Pharmaceutica Health Care	129	Head of Clinical Operations, Key Accout Manager, Déléguée hospitalier specialiste	>100	$100-500M	$7M raised Grant, 12-23-2024	⏸️ No Growth: 0% 129 Employees	⏸️ No Growth: 0% 6 Employees	Actively Hiring	11	Allschwil, Switzerland
22	Sensimed Biotechnology	6	CEO, Accounting And HR Manager, Head of Engineering	+8	$1-10M	$8M raised Series C, 07-10-2013	⏸️ No Growth: 0% 6 Employees	⏸️ No Growth: 0% 2 Employees	Not Hiring	23	Etagnières, Switzerland
23	NovImmune Biotechnology	59	Research assistant, CMC Project Manager, Research Scientist	+73	$10-50M	$29M raised Series C, 01-11-2016	📊 Modest Growth: 5.36% 56 ↗ 59 Employees	⏸️ No Growth: 0% 3 Employees	Not Hiring	20	Plan-les-Ouates, Switzerland
24	Isospec Analytics Bioinformatics	7	Chief Technology Officer, Senior Bioanalytical Scientist, Member of the Board of Advisors	+8	$1-10M	$109k raised Debt Financing, 04-24-2024	⏸️ No Growth: 0% 7 Employees	⏸️ No Growth: 0% 4 Employees	Not Hiring	13	Lausanne, Switzerland
25	Securecell Biotechnology	62	Senior Systems Engineer, Senior Bioprocess Application Support Engineer, Mechanical Engineer	+83	$1-10M		📊 Modest Growth: 6.9% 58 ↗ 62 Employees	⏸️ No Growth: 0% 5 Employees	Not Hiring	20	Urdorf, Switzerland
26	Swissmedic Health Care	293	Head Competence Center IT-Services nonSAP, Head of Division OMCL (Laboratory), Nonclinical Assessor	>100	$10-50M		📊 Modest Growth: 1.03% 290 ↗ 293 Employees	⏸️ No Growth: 0% 5 Employees	Not Hiring	12	Bern, Switzerland
27	Novigenix Biotechnology	22	IP manager, Biomarker Scientist, Senior Data Scientist	+18	$1-10M	$1M raised Grant, 09-24-2024	⏸️ No Growth: 0% 22 Employees	⏸️ No Growth: 0% 4 Employees	Not Hiring	28	Epalinges, Switzerland
28	InSphero Biotechnology	68	BPU Manager, Oncology and immunology team lead, Director Business Development (Europe/DACH)	+69	$10-50M		📊 Modest Growth: 1.49% 67 ↗ 68 Employees	⏸️ No Growth: 0% 7 Employees	Not Hiring	30	Schlieren, Switzerland
29	EUGENEX Biotechnologies Biotechnology	1	Biotechnologin, CEO	+2	$1-10M		⏸️ No Growth: 0% 1 Employees	⏸️ No Growth: 0% Employees	Not Hiring	14	Tägerwilen, Switzerland
30	Artidis Biopharma	68	Electronics Development Specialist, Test Engineer, HR Manager	+65	$1-10M	$27M raised Series A, 05-31-2023	⏸️ No Growth: 0% 68 Employees	⏸️ No Growth: 0% 6 Employees	Actively Hiring	30	Basel, Switzerland
31	Debiopharm Group Health Care	359	Laboratory technician, Bioresearch, Head of Clinical Operations, Systems and Security Administrator	>100	$10-50M		📉 Negative Growth: -0.55% 361 ↘ 359 Employees	⏸️ No Growth: 0% 7 Employees	Actively Hiring	19	Lausanne, Switzerland
32	AbbVie Biotechnology	140	Treasury Analyst, Assistant, Administrative Assistant III	>100	$500-1,000M		📉 Negative Growth: -1.41% 142 ↘ 140 Employees	⏸️ No Growth: 0% 2 Employees	Not Hiring	0	Zürich, Switzerland
33	Xeltis Biotechnology	63	Assoc. Director R&D, Clinical Specialist, Junior Process Engineer	+62	$1-10M	$13M raised Series D, 08-14-2023	📊 Modest Growth: 1.61% 62 ↗ 63 Employees	⏸️ No Growth: 0% 10 Employees	Not Hiring	28	Zürich, Switzerland
34	Invenesis Biotechnology	11	Laboratory Technicians, CEO and co-founder, Collaborateur scientifique	+14	$1-10M		⏸️ No Growth: 0% 11 Employees	⏸️ No Growth: 0% 5 Employees	Not Hiring	20	Saint-Blaise, Switzerland
35	BioVersys Biotechnology	21	Research associate, Head of Laboratory, Chief Financial Officer	+27	$1-10M	$2M raised Grant, 10-22-2024	📊 Modest Growth: 5% 20 ↗ 21 Employees	⏸️ No Growth: 0% 4 Employees	Not Hiring	29	Basel, Switzerland
36	Swiss PharmaCan Pharmaceutical	4	Business Development Executive, Senior Director Sales Marketing	+2	$10-50M		⏸️ No Growth: 0% 4 Employees	⏸️ No Growth: 0% 2 Employees	Not Hiring	33	Frauenfeld, Switzerland
37	Lino Biotech AG Bioinformatics	13	Research Internship, Group Lead Software, Intern – Applications Team	+15	$1-10M		⏸️ No Growth: 0% 13 Employees	⏸️ No Growth: 0% 3 Employees	Not Hiring	18	Zurich, Switzerland
38	Alentis Therapeutics Biopharma	54	Director Translational Data Science, Senior Director Business Development, Global Project Director	+45	$1-10M	$181M raised Series D, 11-12-2024	⏸️ No Growth: 0% 54 Employees	⏸️ No Growth: 0% 16 Employees	Not Hiring	20	Allschwil, Switzerland
39	Swiss BioQuant AG Biotechnology	27	Laboratory Specialist HPLC-MS/MS, Study Director, Study Director	+34	$1-10M		⏸️ No Growth: 0% 27 Employees	⏸️ No Growth: 0% Employees	Not Hiring	10	Reinach, Switzerland
40	Eumedica Pharmaceuticals AG Health Care	18	Senior QA Manager, Quality Change Control, IT Compliance, and Serialization Specialist, Senior Accountant	+22	$1-10M		📊 Modest Growth: 5.88% 17 ↗ 18 Employees	⏸️ No Growth: 0% Employees	Actively Hiring	17	Basel, Switzerland
41	NBE-Therapeutics Health Care	34	Research associate, Chief Scientific Officer, Research Associate	+39	$1-10M	$22M raised Series C, 01-10-2020	📊 Modest Growth: 3.03% 33 ↗ 34 Employees	⏸️ No Growth: 0% 1 Employees	Not Hiring	9	Basel, Switzerland
42	Metch Cosmetics	33	Manufacturing Scientist, QC Technician, Scientist	+27	-		⏸️ No Growth: 0% 33 Employees	⏸️ No Growth: 0% 4 Employees	Not Hiring	14	Bilthoven, Netherlands
43	CovalX Biopharma	17	Account Executive, Senior Digital Marketing Specialist, Inside Sales Associate	+16	$1-10M		⏸️ No Growth: 0% 17 Employees	⏸️ No Growth: 0% 3 Employees	Not Hiring	33	Zurich, Switzerland
44	T3 Pharmaceuticals Biopharma	17	Head of In Vivo Pharmacology, Senior Researcher, PhD student Cancer Immunology	+24	$1-10M		📉 Negative Growth: -5.56% 18 ↘ 17 Employees	⏸️ No Growth: 0% 1 Employees	Not Hiring	6	Basel, Switzerland
45	DiNAQOR Biotechnology	18	Director of Engineering, EVP, Technical Project Manager	+7	$1-10M		⏸️ No Growth: 0% 18 Employees	⏸️ No Growth: 0% 5 Employees	Not Hiring	20	Schlieren, Switzerland
46	EspeRare Biotechnology	12	Research, Innovation & Bioethics Director, Non Executive Board Member, Translational Project Leader	+7	$1-10M		⏸️ No Growth: 0% 12 Employees	⏸️ No Growth: 0% 3 Employees	Not Hiring	8	Geneva, Switzerland
47	Amal Therapeutics Biopharma	28	Protein Research Associate & Analytical Scientist, Chief of Staff, CMC Team Leader	+18	$1-10M	$32M raised Series B, 11-12-2018	📉 Negative Growth: -3.45% 29 ↘ 28 Employees	⏸️ No Growth: 0% 5 Employees	Not Hiring	8	Geneva, Switzerland
48	RocketVax Biotechnology	5	Senior Project Manager, Chairman Of The Board	+2	$1-10M	$2 raised Seed Round, 08-03-2021	⏸️ No Growth: 0% 5 Employees	⏸️ No Growth: 0% 2 Employees	Not Hiring	6	Basel, Switzerland
49	LamKap Bio Group Biopharma	1	Chairman	+1	$1-10M		⏸️ No Growth: 0% 1 Employees	⏸️ No Growth: 0% Employees	Not Hiring	16	Pfäffikon, Switzerland
50	Seneque Biotechnology	5	Business Development Manager, E-commerce Manager, Assistante administrative et aide comptable	+6	$1-10M		⏸️ No Growth: 0% 5 Employees	⏸️ No Growth: 0% 2 Employees	Not Hiring	26	Lausanne, Switzerland
51	Abc biopply ag Biotechnology	3	Chief Scientific Officer, Research And Development Scientist (Preclinical 3D Disease Modelling)	+2	$1-10M		⏸️ No Growth: 0% 3 Employees	⏸️ No Growth: 0% Employees	Not Hiring	13	Solothurn, Switzerland
52	Swiss Biotech Center Biotechnology	6	Scientific Officer, Head of R&D and Production Manager, Scientific officer	+5	$1-10M		⏸️ No Growth: 0% 6 Employees	⏸️ No Growth: 0% Employees	Not Hiring	32	Monthey, Switzerland
53	Bioptron Health Care	11	DIRECTORA, Medical representative, Purchase and Logistics Manager	+16	$1-10M		⏸️ No Growth: 0% 11 Employees	⏸️ No Growth: 0% 2 Employees	Not Hiring	22	Wollerau, Switzerland
54	NCCR RNA AND Disease Biotechnology	2	Administrative Assistant	+1	$10-50M		⏸️ No Growth: 0% 2 Employees	⏸️ No Growth: 0% Employees	Not Hiring	6	Bern, Switzerland
55	Asceneuron Health Care	17	Senior Associate Scientist, Head of Clinical Operations, Chief Executive Officer	+11	$1-10M	$100M raised Series C, 07-16-2024	⏸️ No Growth: 0% 17 Employees	⏸️ No Growth: 0% 4 Employees	Not Hiring	20	Lausanne, Switzerland
56	AC Immune Biopharma	142	IP Manager Chemistry, Regulatory Affairs Associate, Scientific Advisor	>100	$10-50M	$50M raised Post-IPO Equity, 12-15-2023	📊 Modest Growth: 1.43% 140 ↗ 142 Employees	⏸️ No Growth: 0% 8 Employees	Actively Hiring	33	Lausanne, Switzerland
57	Bachem Holding AG Biotechnology	1,190	Technical Author R&D, Senior Project Manager, STA Coach Harmonization Controlling Processes	>100	$100-500M		📊 Modest Growth: 0.68% 1,182 ↗ 1,190 Employees	⏸️ No Growth: 0% 23 Employees	Actively Hiring	55	Bubendorf, Switzerland
58	Molecular Partners Biopharma	130	Senior Director Legal and Data Protection Officer, Principal Research Associate, Associate Director, Translational Medicine	>100	$10-50M	$20M raised Post-IPO Equity, 10-25-2024	📊 Modest Growth: 0.78% 129 ↗ 130 Employees	⏸️ No Growth: 0% 9 Employees	Not Hiring	34	Schlieren, Switzerland
59	Fairmed Healthcare Health Care	9	QA/QC Manager, Senior Financial Controller / Deputy Head of Finance, Assistant Manager	+10	$1-10M		⏸️ No Growth: 0% 9 Employees	⏸️ No Growth: 0% 1 Employees	Not Hiring	9	Zug, Switzerland
60	GeNeuro Biotechnology	8	Non Executive Director, Chief Financial Officer, Comptable - Contrôleur de Gestion	+11	$1-10M	$5M raised Post-IPO Equity, 02-01-2024	⏸️ No Growth: 0% 8 Employees	⏸️ No Growth: 0% 5 Employees	Not Hiring	17	Plan-les-Ouates, Switzerland
61	Biotechgate Biotechnology	10	Head of Commercial, Business Development Executive, COO & Partner	+10	$1-10M		⏸️ No Growth: 0% 10 Employees	⏸️ No Growth: 0% 2 Employees	Not Hiring	20	Zurich, Switzerland
62	Resistell Biotechnology	18	Senior AFM engineer, Chief Operating Officer, IT Project Manager	+14	$1-10M	$9M raised Series B, 12-19-2022	📉 Negative Growth: -5.26% 19 ↘ 18 Employees	⏸️ No Growth: 0% 7 Employees	Not Hiring	14	Muttenz, Switzerland
63	Noorik Biopharmaceuticals Biopharma	2	Corporate Development Manager, CEO	+2	$1-10M		⏸️ No Growth: 0% 2 Employees	⏸️ No Growth: 0% 1 Employees	Not Hiring	5	Basel, Switzerland
64	Neurix Biotechnology	3	R&D Scientist, Scientist	+2	$1-10M	$10k raised Grant, 02-01-2011	🚀 High growth: 50% 2 ↗ 3 Employees	⏸️ No Growth: 0% Employees	Not Hiring	20	Geneva, Switzerland
65	Nuvamid Biotechnology	3	Chief Medical Officer, Scientific Director, R&D Manager	+3	$1-10M		⏸️ No Growth: 0% 3 Employees	⏸️ No Growth: 0% 1 Employees	Not Hiring	18	Lausanne, Switzerland
66	3B Biotech Research Biotechnology	3	Regulatory Affairs Consultant, Clinical Research Associate, โปรแกรมเมอร์	+3	$1-10M		⏸️ No Growth: 0% 3 Employees	⏸️ No Growth: 0% Employees	Not Hiring	24	Balerna, Switzerland
67	IABS - International Alliance for Biological Standardization Biotechnology	8	none, Advisor to The Board at IABS, Chairman	+3	$10-50M		⏸️ No Growth: 0% 8 Employees	⏸️ No Growth: 0% 2 Employees	Not Hiring	21	Geneva, Switzerland
68	MetrioPharm Biotechnology	11	Head of Drug Development, Geschäftsführerin, Senior Legal Counsel	+17	$1-10M	$121k raised Grant, 10-12-2022	📊 Modest Growth: 10% 10 ↗ 11 Employees	⏸️ No Growth: 0% 2 Employees	Not Hiring	9	Zurich, Switzerland
69	NCCR Molecular Systems Engineering Biotechnology	3	Scientific Officer	+1	$10-50M		⏸️ No Growth: 0% 3 Employees	⏸️ No Growth: 0% 1 Employees	Not Hiring	10	Basel, Switzerland
70	ImmunOs Therapeutics Biotechnology	13	Chief Clinical Operations Officer, Business Operations Manager, Chief Scientific Officer	+4	$1-10M	$11M raised Series C, 09-17-2024	⏸️ No Growth: 0% 13 Employees	⏸️ No Growth: 0% 6 Employees	Not Hiring	8	Schlieren, Switzerland
71	InterAx Biotech Biopharma	15	Scientist systems biology, Senior Computational Chemist, Principal Scientist Systems Biology	+8	$1-10M	$2M raised Grant, 09-25-2019	⏸️ No Growth: 0% 15 Employees	⏸️ No Growth: 0% 5 Employees	Not Hiring	22	Schlieren, Switzerland
72	Pentapharm Biotechnology	48	Coordenador de produção, Quality System Team Lead, Working Student	+60	$100-500M		📊 Modest Growth: 2.13% 47 ↗ 48 Employees	⏸️ No Growth: 0% Employees	Actively Hiring	14	Aesch, Switzerland
73	Legacy Healthcare Biotechnology	15	Co-Founder & Board Member, IT & Technical Director, Director (Head) of Clinical Operations (start-up)	+12	$10-50M	$2M raised Grant, 03-29-2022	⏸️ No Growth: 0% 15 Employees	⏸️ No Growth: 0% 6 Employees	Not Hiring	15	Épalinges, Switzerland
74	Medicines for Malaria Venture Biopharma	121	Sr Director, Product Development, Early Development and Safety Associate, Resource Mobilization Coordinator	>100	$10-50M		📊 Modest Growth: 1.68% 119 ↗ 121 Employees	⏸️ No Growth: 0% 12 Employees	Actively Hiring	18	Meyrin, Switzerland
75	Tolremo therapeutics Biopharma	9	Member Board of Directors, Clinical Program Lead, Chief Operating Officer	+9	$1-10M	$3M raised Series A, 09-20-2023	⏸️ No Growth: 0% 9 Employees	⏸️ No Growth: 0% 4 Employees	Not Hiring	11	Basel, Switzerland
76	Addex Therapeutics Health Care	19	Senior Accountant, Technicien ADME-PK, Laboratory Head/Project Leader	+14	$1-10M	$2M raised Post-IPO Equity, 01-31-2024	⏸️ No Growth: 0% 19 Employees	⏸️ No Growth: 0% 3 Employees	Not Hiring	12	Plan-les-Ouates, Switzerland
77	Primex Pharmaceuticals Health Care	9	Medical Sales Representative, Member of the board of directors, non-executive director, Chairman of the Board	+9	$1-10M		⏸️ No Growth: 0% 9 Employees	⏸️ No Growth: 0% 5 Employees	Not Hiring	19	Zug, Switzerland
78	Biofluid Systems SA Biotechnology	1	Dyrektor, CEO, Owner	+3	$1-10M		⏸️ No Growth: 0% 1 Employees	⏸️ No Growth: 0% 1 Employees	Not Hiring	6	Chamblon, Switzerland
79	Endogena Therapeutics Biopharma	5	Director of Translational Medicine, Chief Development Officer	+2	$1-10M	$21M raised Series A, 12-13-2021	⏸️ No Growth: 0% 5 Employees	⏸️ No Growth: 0% 3 Employees	Not Hiring	18	Zurich, Switzerland
80	Bucher Biotec Bioinformatics	4	Product Line Manager, Service Manager, Product Manager	+5	$1-10M		⏸️ No Growth: 0% 4 Employees	⏸️ No Growth: 0% Employees	Not Hiring	8	Basel, Switzerland
81	Selmod Biopharma	2	CEO, COO	+2	$1-10M		⏸️ No Growth: 0% 2 Employees	⏸️ No Growth: 0% 2 Employees	Not Hiring	3	Basel, Switzerland
82	MedXCell Biotechnology	5	Chief Executive Officer, Finance and Communication Analyst, Partenaire et développeur	+3	$1-10M	$5M raised Series A, 06-04-2021	⏸️ No Growth: 0% 5 Employees	⏸️ No Growth: 0% 2 Employees	Not Hiring	16	Montreux, Switzerland
83	Spirochrome Biotechnology		Co-Founder	+1	$100-500M		⏸️ No Growth: 0% Employees	⏸️ No Growth: 0% Employees	Not Hiring	20	Stein am Rhein, Switzerland
84	Genpax Biotechnology	32	Investor, Head of Engineering, Bioinformatician (Computational Biologist)	+21	$1-10M	$2M raised Seed Round, 03-01-2022	📉 Negative Growth: -5.88% 34 ↘ 32 Employees	⏸️ No Growth: 0% 3 Employees	Not Hiring	24	Gstaad, Switzerland
85	Scailyte Biotechnology	21	Chief Financial Officer, Head of GenAI Adoption, Senior IT Engineer	+12	$1-10M	$1M raised Series A, 12-04-2023	⏸️ No Growth: 0% 21 Employees	⏸️ No Growth: 0% 7 Employees	Not Hiring	40	Basel, Switzerland
86	Rbv Capital Biotechnology		Офис-менеджер, Assistant, Banker	+6	$1-10M		⏸️ No Growth: 0% Employees	⏸️ No Growth: 0% Employees	Not Hiring	7	Zug, Switzerland
87	mayba.ch AG Health Care	7	thitx, Responsable des ventes, ministrador de empresas	+15	$1-10M		📊 Modest Growth: 16.67% 6 ↗ 7 Employees	⏸️ No Growth: 0% 2 Employees	Not Hiring	8	Pully, Switzerland
88	Spexis AG Biopharma	18	Head CMC, ADME scientist, Senior Scientist in Peptide Chemistry	+17	$10-50M		⏸️ No Growth: 0% 18 Employees	⏸️ No Growth: 0% 4 Employees	Not Hiring	22	Allschwil, Switzerland
89	Micreos Biopharma	33	Director of Protein Engineering, Chief Scientific Officer, Director Pre-Clinical Operations	+12	$10-50M		⏸️ No Growth: 0% 33 Employees	⏸️ No Growth: 0% 4 Employees	Not Hiring	16	Baar, Switzerland
90	Mabylon AG Biotechnology	19	Research Associate, Senior Scientist Protein Engineering, Chairman of the Board	+20	$1-10M	$1M raised Grant, 09-24-2024	⏸️ No Growth: 0% 19 Employees	⏸️ No Growth: 0% 5 Employees	Not Hiring	13	Schlieren, Switzerland
91	ADIENNE Pharma AND Biotech Biotechnology	70	Documentation Specialist, QC Specialist, Specialista QC microbiologia	+81	$10-50M		⏸️ No Growth: 0% 70 Employees	⏸️ No Growth: 0% 4 Employees	Not Hiring	24	Lugano, Switzerland
92	Safi Swiss Research Biotechnology	13	Director Board of Directors, Regional Area Manager, Assistant General Manager	+12	$1-10M		⏸️ No Growth: 0% 13 Employees	⏸️ No Growth: 0% 4 Employees	Actively Hiring	12	Lugano, Switzerland
93	Berlin Cures Holding AG Biotechnology	6	Director, Senior Manager Regulatory Affairs & CMC, Co-Founder & Member of the Board	+4	$1-10M		⏸️ No Growth: 0% 6 Employees	⏸️ No Growth: 0% 4 Employees	Not Hiring	4	Zug, Switzerland
94	Histide Biotechnology	6	Research Scientist, Regenerative Medicine, Information Technology Researcher, Shareholder	+6	$1-10M	$4M raised Series A, 11-10-2014	⏸️ No Growth: 0% 6 Employees	⏸️ No Growth: 0% 3 Employees	Not Hiring	12	Schindellegi, Switzerland
95	PharmaBiome Bioinformatics	9	Co-Founder, Scientist, Responsable de projet	+9	$1-10M	$1M raised Convertible Note, 07-08-2020	📉 Negative Growth: -10% 10 ↘ 9 Employees	⏸️ No Growth: 0% 5 Employees	Not Hiring	13	Zurich, Switzerland
96	Innomedica Nanotechnology	35	Scientist Quality Control and Analytics, Quality Designer Pharma, Regulatory Affairs Specialist	+37	$1-10M	$16M raised Venture Round, 11-26-2021	📉 Negative Growth: -2.78% 36 ↘ 35 Employees	⏸️ No Growth: 0% 4 Employees	Not Hiring	10	Bern, Switzerland
97	DAMIAN Pharma Biotechnology	2	CEO, Chief Operations Officer	+2	$1-10M		⏸️ No Growth: 0% 2 Employees	⏸️ No Growth: 0% 2 Employees	Not Hiring	9	Walchwil, Switzerland
98	PolyGene Genetics	4	Founder & CEO, Researcher, Sales and Business Development	+4	$1-10M		⏸️ No Growth: 0% 4 Employees	⏸️ No Growth: 0% 1 Employees	Not Hiring	26	Rümlang, Switzerland
99	AMR Industry Alliance Biotechnology	8	Board Member, Secretariat Lead, Board Member	+3	$1-10M		⏸️ No Growth: 0% 8 Employees	⏸️ No Growth: 0% 4 Employees	Not Hiring	26	Geneva, Switzerland
100	Arcoscreen Biotechnology	1	CEO and co-founder at ArcoScreen	+1	$1-10M	$100k raised Debt Financing, 10-12-2022	⏸️ No Growth: 0% 1 Employees	⏸️ No Growth: 0% Employees	Not Hiring	9	Lausanne, Switzerland

Explore more insights

Market Expansion

Top Pharmaceutical Companies in Switzerland

14 October 2025

By Surfe

588

Market Expansion

Top Energy Companies in Switzerland

14 October 2025

By Surfe

239

Market Expansion

Top Aerospace Companies in Switzerland

11 October 2025

By Surfe

190

Growth

Top Logistics Companies in Germany

14 October 2025

By Surfe

173

100

Market Expansion

Top Agriculture Companies in Germany

14 October 2025

By Surfe

151

Market Expansion

Top Financial Services Companies in Germany

14 October 2025

By Surfe

144

100

Market Expansion

Top Energy Companies in Germany

14 October 2025

By Surfe

131

Growth

Top FinTech Companies in Germany

14 October 2025

By Surfe

123

Market Expansion

Top Pharmaceutical Companies in Spain

14 October 2025

By Surfe

120

Growth

Top SaaS Companies in Germany

14 October 2025

By Surfe

111

100

Intelligent Prospecting, Backed by Signals

What criteria do top biopharma companies in Switzerland use to evaluate vendor credibility and product effectiveness?

Swiss biopharma buys proof, not promises. In these accounts, credibility starts with a dossier mindset. They want to see that your product survives the same scrutiny their drugs do. That means clear evidence of outcomes, a clean quality story, and zero surprises when QA or Swissmedic looks under the hood. Translate features into risk removed and time saved. If you can show shorter release cycles, fewer deviations, faster site startup, or higher enrollment velocity, you are speaking their language. No evidence, no entry.

What gets weighed in the room? Independent validation beats marketing. Peer-reviewed data, real-world results from comparable sites, and measurable impact on speed, quality, or cost. Compliance is the currency. Expect questions on GMP or GxP alignment, Annex 11 or 21 CFR Part 11 readiness, audit trails, and change control. Security and privacy are table stakes, with requests for ISO 27001 or SOC 2 and clear data residency. Operational reliability matters: uptime SLAs, support responsiveness, training plans, and business continuity. Supply continuity is pivotal for anything physical. Think lead times, dual sourcing, lot-to-lot consistency, and certificates of analysis. Integration is about friction. Can it slot into SAP, LIMS, or clinical workflows without a six-month IT project. References from peer biopharma in DACH or EU carry extra weight. Local presence and language support help. ESG is not fluff in Switzerland. Ethical sourcing and a credible sustainability plan can be tie-breakers.

Conversation starters you can use:
- What quality and security checkpoints must a new vendor clear before you can deploy at a site or trial?
- Which 2 or 3 metrics would prove value in the first 90 days?
- Where does this sit in your validation and change control process?
- What evidence carries most weight for your team: peer-reviewed, audited pilot, or reference sites?
- What data residency or privacy constraints must we meet in Switzerland and the EU?
- How do you measure supply risk and continuity for this category?
- Who signs off across QA, IT, clinical, and procurement, and in what order?

Sell confidence, not features. If it is not validated, it is not viable.

What are the most common purchasing objections faced by sales teams when selling to biopharma companies in Switzerland, and how can these be effectively addressed?

The fastest way to stall a deal in Swiss biopharma is not price. It is proof. Buyers want to see that what you sell is validation ready, integrates cleanly, and keeps sensitive data inside Switzerland or the EU. Lead with that. Treat validation, privacy, and integration as the opening act, not the appendix. Memorable line to use: If it is not validated, it is not viable. Make it tangible. Offer a clear path for GxP needs with EU Annex 11 and 21 CFR Part 11 readiness, show a sample validation plan, and outline who signs off in QA. Then cut risk on day one. Propose a low scope pilot in a non GxP workflow, set exit criteria, and map the step to full validation. Pair it with data residency clarity. State your hosting options in Switzerland or the EU, your DPA and subprocessor list, and how identity, audit trails, and encryption are handled. Another line that lands in Basel and Zug: No EU or Swiss data option, no deal.

Two more objections appear early. Integration fear and global governance. Your buyers worry about breaking SAP, Veeva, LIMS, or QMS flows and triggering change control. Defuse it with a simple diagram of how you fit, named systems you have worked with, and a sandbox timeline. Ask questions that move them forward: Which site or study can we start with that is non GxP but high impact. What is the validation pack your QA expects on day one. What data must remain in Switzerland for FADP and GDPR. Who at global IT or QA needs to see the integration plan before a pilot. When they push on cost, shift to cost of delay. Tie your outcome to batch release time, deviation rework, or study start-up timelines. Offer flexible commercials that match procurement cycles and a path from one site to global template.

Net message for your team: start with risk removal, not features. Speak to QA and data privacy in the first email. Show one reference from a peer in Switzerland. Speed wins only when QA is on board.

How can understanding the decision-making hierarchy within top biopharma companies enhance your sales strategy?

Chasing a logo like Novartis, Roche, or Lonza without a map of who actually moves the deal is like trying to win a relay while running alone. In Swiss biopharma, decisions are matrixed. Global HQ sets standards, site leaders execute, and buying authority lives inside cross functional committees. When you understand that hierarchy, you stop pitching features to the wrong person and start aligning outcomes to the people who carry risk. R&D leaders care about trial speed and protocol adherence. Tech Ops cares about yield, release timelines, and continuity. Quality worries about findings and recalls. Procurement protects cost and vendor risk. IT and Security guard data and compliance. Speak to each, in their language, and you shorten cycles, avoid surprise reviews, and turn a pilot at one site into a global template. Titles do not buy. Buying centers do.

This is not just politics. It is revenue timing. Miss the steering committee, and you slip a quarter. Ignore vendor risk reviews, and your champion burns political capital. Swiss HQs often centralize standards. That means one global green light can unlock multiple affiliates and sites. Sequence your path. Win a site level proof, equip your champion for the global review, and pre clear procurement, security, and quality. If you do not know who signs the risk memo, you are not in the deal.

Use these talk tracks to make progress fast:
- Who owns the business outcome and who owns the risk if this fails?
- Which committee gives the final yes, and how often do they meet?
- For your last similar buy, which functions had veto power?
- What must be proven in a site pilot before global adoption is considered?
- How are budgets split between program teams and central platforms this quarter?
- What non negotiables will Quality, Security, and Legal require to proceed?
- Where are the decision makers based HQ or site and who prepares the brief?
- What deadlines matter trial start, tech transfer, validation, or launch readiness?
- If we removed one approval step, which would save you the most time?

Map the maze before you knock on doors. Efficiency beats force every time.

What are the specific pain points of biopharma companies in Switzerland that your product or service directly addresses?

Swiss biopharma leads in science while wrestling with commercial complexity. Three pains surface fast. First, compliance friction. Every touchpoint must align with Swissmedic guidance and the updated FADP, and any ambiguity stalls outreach. Second, stakeholder sprawl. Buying groups span Basel HQ, EU affiliates, and cantonal hospitals, with different languages and incentives. Third, timing risk. Trial readouts, Swissmedic decisions, and FOPH reimbursement steps open narrow windows. When data is scattered or outdated, launches slip, tenders get missed, and rivals set the story. Slow is expensive in pharma.

What moves the needle is simple and specific. Clean, Swiss-specific account intelligence that maps real decision paths across medical, regulatory, HEOR, procurement, and pharmacy. Multilingual contact context that avoids duplicate outreach and confusion between sites and affiliates. Signal-driven prioritization tied to trial milestones, approval news, reimbursement updates, and hospital formulary changes, so teams act the day the market shifts. Transparent consent capture and audit trails that make legal comfortable and free reps to sell. Clear meeting notes that flow to the next owner, so momentum does not die between teams. If you cannot see the buying group, you cannot shorten the cycle. Compliance is a growth strategy in Switzerland.

Use these conversation starters to land the pain:
- How do you prove FADP and Swissmedic compliance for outbound and events without slowing the team?
- When Swissmedic or FOPH news hits, how do you reprioritize accounts the same day?
- Who actually signs at the cantonal level for your therapy, and who blocks, in German, French, and Italian regions?
- How do you prevent duplicate outreach to KOLs across HQ and affiliates?
- What signals tell you a tender or protocol change is about to open, not already closed?

How can sales teams use technological tools to streamline the prospecting process and increase accuracy in targeting decision-makers within Swiss biopharma companies?

Here is the fastest win: stop treating Swiss biopharma as one big logo and start selling to live programs. Tech makes that shift practical. Pull your target list into your CRM, then enrich it with therapy area, trial phase, and site locations from ClinicalTrials.gov and Swissmedic announcements. Layer on news and hiring signals to spot movement like a new CMC lead in Visp or a Basel trial flipping to Phase 3. Use LinkedIn Sales Navigator to map the buying circle by function, not job level. In this sector, Clinical Ops, Regulatory, QA, CMC, Market Access, and Procurement often share the pen. Build that committee in your CRM and score accounts by signal strength. The result is less spray and pray and more precision on the people who actually own the problem. Prospecting without signals is guessing with a quota.

Tighten execution with a simple workflow. Segment by canton and language to boost reply rates, especially across Basel Stadt, Zug, and the Lake Geneva corridor. Verify every contact to cut bounce and protect domain health. Route program-specific insights into your first line, not the third paragraph. Two lines of context beat a 10-line pitch. Sell to the program, not the company.

Use these conversation starters to land with credibility:
- I saw your Phase 2 in immunology just opened sites in Vaud. Where are monitoring costs creating the most drag on cycle time right now?
- Your team posted for a Head of Quality in Zug. Are you expanding release testing capacity or solving a backlog before scale-up?
- Swissmedic shows a recent approval in oncology. What changed in your vendor stack to hit submission timelines, and where are gaps still showing up?
- Noticed a new partnership in cell therapy. Who owns tech evaluation for chain of identity and what does a good pilot look like for you?

If you want a stack you can spin up this week, keep it simple. Use a data provider plus LinkedIn Sales Navigator for committee mapping, ClinicalTrials.gov and Swissmedic alerts for triggers, a news scraper for funding and partnerships, an enrichment and verification tool for clean contacts, and your outreach platform for language-personalized sequences. The payoff is fewer dials, better meetings, and a pipeline that mirrors where Swiss biopharma is actually moving.

In what ways can personalized sales pitches increase engagement and conversion rates with top biopharma executives?

Generic pitches are white noise in Basel boardrooms. Personalized outreach cuts through because it signals you understand the executive’s real scoreboard. In biopharma that scoreboard is not clicks or seats. It is trial timelines, launch revenue, risk and compliance, and uninterrupted supply. When you anchor your message to a live therapy area, a current study on ClinicalTrials.gov, a recent manufacturing expansion, or a point from their last earnings call, you move from vendor to partner. That relevance earns attention, shortens the credibility gap, and raises the odds of a call. Executives respond when they sense you can remove risk from their quarter. Specificity is the new credibility.

Make your personalization practical, not flattery. Use a clean formula: observation, metric, stakes, ask. For example: “You flagged enrollment pressure in oncology across DACH in Q2. Where is time slipping between site selection and first patient in, and what would a 15 percent faster start mean for the launch window.” Or: “Saw the new biologics capacity coming online in Visp. How are you protecting lot release cycle time during tech transfer, and what does a one week delay do to service levels for EU tenders.” Or: “Your rare disease team is scaling field interactions across CH and DE. What is the plan to prioritize accounts where access hurdles risk the first six months of revenue.” These are short, pointed, and tied to outcomes the executive reports up. A simple rule to share with your team: lead with the metric they own, not the feature you built. Another keeper: make the email about their risk, not your roadmap. Personalized pitches work because they translate your value into their P&L and timeline, which is the only language that converts.